It’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis, said Sean C. Dowdy, MD, chair, division of gynecologic surgery, department of obstetrics and gynecology, Mayo Clinic.
It’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis, said Sean C. Dowdy, MD, chair, division of gynecologic surgery, department of obstetrics and gynecology, Mayo Clinic.
Transcript
What interventions have been put in place to reduce opioid abuse in patients undergoing surgery for gynecologic malignancies?
The first part is just awareness. I think it’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis. For instance, Prince and Tom Petty, they didn’t die of heroin overdoses, they died of prescription fentanyl overdoses. So, while I think the pharmaceutical companies bare some responsibility, the fact is that patients get their prescriptions from physicians, so we really need to take charge of this and have a response to how to deal with this.
So, the first past is awareness. The second apart is, again, just making a change to our practice. We need to inject incisions so patients have better pain control, we need to optimize nonopioid alternatives, like ibuprofen and Tylenol, and patients need to be educated about this, as well. We shouldn’t just give every patient a prescription for oxycodone when they leave the hospital. They should only get it if they need it, and if they get these prescriptions, they should be in relatively small amounts.
For example, for patients with ovarian cancer surgery, this is a big laparotomy from pubic synthesis to xiphoid process, our guidelines are that the patients only get 10 pills when they leave the hospital. We have not seen an increase in refills, and patients still have good pain scores. So, really, we’ve been overprescribing pretty significantly before that change.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More